| Bioactivity | SBI-115 is a TGR5 (GPCR19) antagonist. SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5[1]. | ||||||||||||
| Invitro | SBI-115 (100-200 µM, 24 hours) inhibits proliferation triggered by pre-treatment of cystic cholangiocytes with Taurolithocholic acid (TLCA) in shRNA-transfected ADPKD cholangiocytes[1]. Cell Proliferation Assay[1] Cell Line: | ||||||||||||
| Name | SBI-115 | ||||||||||||
| CAS | 882366-16-7 | ||||||||||||
| Formula | C14H13ClN2O4S | ||||||||||||
| Molar Mass | 340.78 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Masyuk TV, et al. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling. Hepatology. 2017 Oct; 66(4):1197-1218. |
SBI-115
CAS: 882366-16-7 F: C14H13ClN2O4S W: 340.78
SBI-115 is a TGR5 (GPCR19) antagonist. SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibit
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.